ASCO 2019: Effectiveness of pazopanib after kidney cancer metastasectomy

In this phase III study, presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago this week, the use of treatment with pazopanib after surgery to remove renal cell carcinoma (RCC) metastases (metastasectomy) was investigated. One hundred and twenty-nine patients with no evidence of disease after surgery to remove RCC metastases […]

read more

Four distinct subgroups of clear cell renal cancer identified

Using gene profiling, a recent study published in Cancer Discovery has identified four distinct molecular subgroups associated with response to treatment with sunitinib or pazopanib and survival. The findings demonstrate the effects of the presence of immune cells and angiogenesis on the effectiveness of sunitinib and pazopanib against the cancer, and are important for individualised decision-making. […]

read more

ESOU 2019: First-line treatment for metastatic renal cell carcinoma – where do we stand?

The following review of the literature for first-line treatment of metastatic renal cell carcinoma (RCC) was presented at the European Association of Urology (EAU) Section of Oncological Urology (ESOU) conference in Prague, Czech Republic last week. The current paradigm for the first- and second-line treatment of RCC was presented based upon patient risk according to the International Metastatic Renal […]

read more

Safety and efficacy of nivolumab plus TKI combinations in advanced kidney cancer

A phase 1 study has evaluated the safety and efficacy of nivolumab in combination with sunitinib and pazopanib in people with advanced renal cell carcinoma (RCC). Although there were good responses to the nivolumab plus sunitinib  and nivolumab plus pazopanib combinations and progression-free survival (PFS) was encouraging (12.7 and 7.2 months respectively), the side effect […]

read more

Potential biomarkers may predict response to TKIs in metastatic kidney cancer

A recent study published in Clinical Cancer Research and conducted in France has identified potential biological markers that are related to the formation of new blood vessels (angiogenesis) and regulated by the levels of oxygen reaching the tissues (hypoxia). These biomarkers have been found to be strong predictors of response, progression-free survival (PFS), and overall survival […]

read more

Implications of real world data on the use of first-line pazopanib for the management of metastatic kidney cancer

The following interview with Dr Eric Jonasch, medical oncologist from MD Anderson Cancer Centre in Texas, USA, discusses the implications of real world data on the use of first-line pazopanib for the management of metastatic renal cell carcinoma (RCC). Dr Jonasch was interviewed at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week. Watch Dr Jonasch’s interview […]

read more

Real world experience with pazopanib in patients with advanced/metastatic kidney cancer

Results from the PRINCIPAL study to evaluate the real world effectiveness and safety of pazopanib in patients with advanced/metastatic renal cell carcinoma (RCC) were presented at the 2018 American Society for Clinical Oncology (ASCO) meeting in Chicago this week. PRINCIPAL is the largest prospective real world study of pazopanib in patients with RCC. All patients aged […]

read more

Adjuvant therapy with TKIs has no benefit for high-risk kidney cancer

According to the results of a recent meta-analysis of three phase III studies, adjuvant therapy with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) has no compelling benefit in the treatment of high-risk renal cell carcinoma (RCC). The meta-analysis was presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting this week. […]

read more

Status of adjuvant therapy for the treatment of kidney cancer

Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an overview of adjuvant therapy with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) in patients with high-risk renal cell carcinoma (RCC) at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month. Over the past few years, three […]

read more

Tyrosine kinase inhibitors for kidney cancer: Past, present and future

In his keynote lecture at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month, Dr Robert Motzer from Memorial Sloan Kettering Cancer Center in New York discussed the past, present and future of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) for the treatment of advanced/metastatic renal cell carcinoma […]

read more
Showing 1 to 10 of 21 results
  TOP